3C
ABBV icon

361 Capital’s AbbVie ABBV Stock Holding History

361 Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,901
Closed -$454K – 317
2018
Q2 		$454K Buy
+4,901
New +$479K 0.1% 290
2017
Q3 		– Sell
-106,996
Closed -$7.76M – 250
2017
Q2 		$7.76M Buy
106,996
+5,832
+6% +$392K 1.31% 25
2017
Q1 		$6.59M Buy
+101,164
New +$6.36M 1.41% 28

Other funds holding ABBV

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

361 Capital's ABBV Position: Q3 2018 in Review

361 Capital sold out of AbbVie (ABBV) in Q3 2018, closing a stake of 4,901 shares — an estimated $454K sold.

361 Capital first reported a position in ABBV in Q1 2017 and held it in 3 quarters. The position peaked at $7.76M in Q2 2017. 1,956 funds tracked by Wall St. Rank hold ABBV as of Q3 2018.

  • 361 Capital reported no remaining AbbVie position as of Q3 2018 after selling out during the quarter.
  • 361 Capital sold 4,901 AbbVie shares in Q3 2018, an estimated $454K.
  • 361 Capital first reported a position in AbbVie in Q1 2017 and held it in 3 quarters.
  • 361 Capital's AbbVie position peaked at $7.76M in Q2 2017.
  • 1,956 funds tracked by Wall St. Rank held AbbVie as of Q3 2018.

Based on 361 Capital's 13F filing for Q3 2018, filed 13 Nov 2018.